This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Shane Olwill Biography and Net Worth

Insider of Pieris Pharmaceuticals

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

How old is Shane Olwill?: Dr. Olwill is currently 48 years old. There are 2 older executives and no younger executives at Pieris Pharmaceuticals. The oldest executive at Pieris Pharmaceuticals is Mr. Thomas Bures, Senior VP, CFO & Treasurer, who is 49 years old. Learn More on Shane Olwill's age.
How do I contact Shane Olwill?: The corporate mailing address for Dr. Olwill and other Pieris Pharmaceuticals executives is 255 State Street 9th Floor, Boston MA, 02109. Pieris Pharmaceuticals can also be reached via phone at (857) 246-8998 and via email at [email protected]. Learn More on Shane Olwill's contact information.
Has Shane Olwill been buying or selling shares of Pieris Pharmaceuticals?: Shane Olwill has not been actively trading shares of Pieris Pharmaceuticals in the last ninety days. Most recently, Shane Olwill sold 480 shares of the business's stock in a transaction on Monday, August 30th. The shares were sold at an average price of $408.80, for a transaction totalling $196,224.00. Learn More on Shane Olwill's trading history.
Are insiders buying or selling shares of Pieris Pharmaceuticals?: During the last year, Pieris Pharmaceuticals insiders bought shares 3 times. They purchased a total of 6,001 shares worth more than $92,311.00. The most recent insider tranaction occured on August, 12th when Major Shareholder Adar1 Capital Management, Llc bought 3,000 shares worth more than $47,640.00. Insiders at Pieris Pharmaceuticals own 6.4% of the company. Learn More about insider trades at Pieris Pharmaceuticals.
Information on this page was last updated on 8/12/2024.

Shane Olwill Insider Trading History at Pieris Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/30/2021	Sell	480	$408.80	$196,224.00

Shane Olwill Buying and Selling Activity at Pieris Pharmaceuticals

Pieris Pharmaceuticals Company Overview

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $13.60

$13.26

$15.35

50 Day Range

MA: $16.20

$13.60

$17.30

2 Week Range

Now: $13.60

$6.20

$22.32

Volume

51,700 shs

Average Volume

45,988 shs

Market Capitalization

$17.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61